Michael Ulz
Stock Analyst at Morgan Stanley
(3.82)
# 749
Out of 4,749 analysts
110
Total ratings
47.27%
Success rate
11.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Maintains: Overweight | $46 → $96 | $54.08 | +77.51% | 4 | Jan 28, 2025 | |
| SLN Silence Therapeutics | Reiterates: Overweight | $49 | $5.33 | +819.32% | 10 | Oct 8, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Overweight | $105 | $32.75 | +220.61% | 2 | Sep 12, 2024 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $48 → $52 | $14.22 | +265.68% | 2 | Aug 14, 2024 | |
| YMAB Y-mAbs Therapeutics | Maintains: Underweight | $12 → $11 | $5.97 | +84.25% | 6 | Aug 13, 2024 | |
| THRD Third Harmonic Bio | Upgrades: Overweight | $12 → $20 | $5.26 | +280.23% | 4 | Aug 9, 2024 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $110 → $115 | $112.53 | +2.19% | 9 | Jul 12, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $250 → $255 | $271.31 | -6.01% | 8 | Jul 12, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $53 → $57 | $48.88 | +16.61% | 3 | Jun 18, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Equal-Weight | $36 → $27 | $19.88 | +35.81% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $3.24 | +1,134.57% | 1 | Mar 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.30 | +438.46% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $1.84 | +878.26% | 1 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $23 → $12 | $9.42 | +22.08% | 4 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $25 | $2.39 | +946.03% | 5 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $48 | $31.90 | +50.47% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $10.42 | +159.12% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $4 | $0.62 | +542.98% | 4 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $23 | $5.85 | +293.16% | 3 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $4.36 | +358.72% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $10.74 | +318.99% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.71 | +1,318.44% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $8 | $0.24 | +3,230.56% | 5 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $1.50 | +100.00% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $10.40 | +188.46% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $30 | $1.51 | +1,886.75% | 3 | Mar 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $7.54 | +496.82% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $20 | $0.61 | +3,184.61% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $43.03 | +85.92% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $9.58 | +56.58% | 3 | Jul 12, 2017 |
Akero Therapeutics
Jan 28, 2025
Maintains: Overweight
Price Target: $46 → $96
Current: $54.08
Upside: +77.51%
Silence Therapeutics
Oct 8, 2024
Reiterates: Overweight
Price Target: $49
Current: $5.33
Upside: +819.32%
Viking Therapeutics
Sep 12, 2024
Reiterates: Overweight
Price Target: $105
Current: $32.75
Upside: +220.61%
Dyne Therapeutics
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $14.22
Upside: +265.68%
Y-mAbs Therapeutics
Aug 13, 2024
Maintains: Underweight
Price Target: $12 → $11
Current: $5.97
Upside: +84.25%
Third Harmonic Bio
Aug 9, 2024
Upgrades: Overweight
Price Target: $12 → $20
Current: $5.26
Upside: +280.23%
Blueprint Medicines
Jul 12, 2024
Maintains: Equal-Weight
Price Target: $110 → $115
Current: $112.53
Upside: +2.19%
Alnylam Pharmaceuticals
Jul 12, 2024
Maintains: Equal-Weight
Price Target: $250 → $255
Current: $271.31
Upside: -6.01%
Mirum Pharmaceuticals
Jun 18, 2024
Maintains: Overweight
Price Target: $53 → $57
Current: $48.88
Upside: +16.61%
Arrowhead Pharmaceuticals
May 13, 2024
Maintains: Equal-Weight
Price Target: $36 → $27
Current: $19.88
Upside: +35.81%
Mar 4, 2024
Initiates: Overweight
Price Target: $40
Current: $3.24
Upside: +1,134.57%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.30
Upside: +438.46%
Feb 27, 2024
Initiates: Overweight
Price Target: $18
Current: $1.84
Upside: +878.26%
Jan 5, 2024
Downgrades: Underweight
Price Target: $23 → $12
Current: $9.42
Upside: +22.08%
Nov 29, 2023
Maintains: Overweight
Price Target: $28 → $25
Current: $2.39
Upside: +946.03%
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $45 → $48
Current: $31.90
Upside: +50.47%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $10.42
Upside: +159.12%
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $5 → $4
Current: $0.62
Upside: +542.98%
May 23, 2023
Maintains: Outperform
Price Target: $20 → $23
Current: $5.85
Upside: +293.16%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $4.36
Upside: +358.72%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $10.74
Upside: +318.99%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.71
Upside: +1,318.44%
Jan 27, 2023
Maintains: Equal-Weight
Price Target: $6 → $8
Current: $0.24
Upside: +3,230.56%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $1.50
Upside: +100.00%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $10.40
Upside: +188.46%
Mar 30, 2022
Maintains: Equal-Weight
Price Target: $25 → $30
Current: $1.51
Upside: +1,886.75%
Oct 8, 2020
Initiates: Outperform
Price Target: $45
Current: $7.54
Upside: +496.82%
May 28, 2020
Maintains: Outperform
Price Target: $12 → $20
Current: $0.61
Upside: +3,184.61%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $43.03
Upside: +85.92%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $9.58
Upside: +56.58%